GRFS - Grifols: Short-Term Turbulence But Long-Term Upside February, 10 2022 12:09 AM Grifols S.A. Grifols currently trading at a 30% discount to European specialty pharma. Biotest AG Investment analysis. Biotest R&D not priced in. For further details see: Grifols: Short-Term Turbulence But Long-Term Upside